Stockreport

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform [Yahoo! Finance]

NLS Pharmaceutics Ltd. - Common Shares  (NLSP) 
PDF Medications activating dual OX1R/OX2R target a broader range of mechanisms involved in neurologic disorders including narcolepsy and other hypersomnolence disorders A [Read more]